Company intelligence / Profile preview

iOrganBio

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

iOrganBio is a biotechnology company specializing in the development of advanced "Organ-on-a-Chip" (OoC) and organoid technologies. The company provides high-fidelity human physiological models that simulate the microenvironment of human organs to improve the accuracy of drug toxicity and efficacy testing. By integrating microfluidics, bio-printing, and stem cell biology, iOrganBio aims to replace traditional animal testing and accelerate the drug discovery process. Their platform includes models for the liver, kidney, and various tumor types, catering to pharmaceutical companies and research institutions globally.

Therapeutic areas: OncologyNephrologyGastroenterology
Modalities: Organ-on-a-chipOrganoidsMicrofluidics
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on iOrganBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iOrganBio.

Explore the full profile